Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Research from C. Mennuni and co-authors provides new data about cancer vaccines
January 28th, 2009
"The telomerase reverse transcriptase, TERT, is an attractive target for human cancer vaccination because its expression is reactivated in a conspicuous fraction of human tumors. Genetic vaccination with murine telomerase (mTERT) could break immune tolerance in different mouse strains and resulted in the induction of both CD4(+) and CD8(+) telomerase-specific T cells," scientists writing in the journal Cancer Research report. "The mTERT-derived immunodominant epitopes recognized by CD8(+) T cells were further defined in these mouse strains and used to track immune responses. Antitumor efficacy of telomerase-based vaccination was investigated in two cancer models...
Source: Vaccine Weekly (2009-01-28)
|
